Goodwill and Intangible Assets

12 Months Ended

Mar. 31, 2013

Note 5. Goodwill and Intangible Assets

The change in the carrying amount of goodwill was as follows (in thousands):

	Biological Indicators		Instruments		Total
April 1, 2011	$	9,279	$	5,171	$	14,450
Acquisitions	—		—		—
March 31, 2012	9,279		5,171		14,450
Acquisitions	—		9,190		9,190
March 31, 2013	$	9,279	$	14,361	$	23,640

Other intangible assets are as follows:

	March 31, 2013
(In thousands)	Carrying Amount		Accumulated Amortization		Net		Useful Life (Years)
Intellectual property	$	4,991	$	1,037	$	3,954	10-16
Trade names	2,296		248		2,048		10
Customer relationships	14,485		5,345		9,140		7-8.5
Non-compete agreements	823		547		276		3-5
	$	22,595	$	7,177	$	15,418

	March 31, 2012
	Carrying Amount		Accumulated Amortization		Net		Useful Life (Years)
Intellectual property	$	4,091	$	542	$	3,549	10-16
Trade names	1,596		27		1,569		10
Customer relationships	8,185		3,555		4,630		7-8.5
Non-compete agreements	523		452		71		3-5
	$	14,395	$	4,576	$	9,819

The following is estimated amortization expense for the years ending March 31:

(In thousands)
2014	$	2,355
2015	2,324
2016	2,304
2017	2,186
2018	2,043

Amortization expense for the years ended March 31, 2013, 2012 and 2011was $2,601,000, $1,490,000 and $1,183,000, respectively.

For the year ended March 31, 2012, we determined that the carrying value of an indefinite-lived trade name intangible asset was greater than its estimated fair value and recorded an impairment loss of $350,000, which is disclosed separately on the accompanying statements of income. Fair value was estimated using the royalty replacement approach, whereby a royalty percentage is applied to forecasted revenues and discounted to determine the present value. While gross profit and cash flows showed improvement since the intangible asset was acquired, revenues did not grow at the level originally used to value the intangible asset. This impairment impacted the Instruments segment.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details